^
    Back
    Association details:
    Biomarker:PIK3CA E542K
    Cancer:Gastric Cancer
    Drug:risovalisib (CYH33) (PIK3CA inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Nat Commun
    Title:

    First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors

    Published date:
    11/16/2022
    Excerpt:
    One patient with gastric cancer (PIK3CA E542K mutation) achieved a PR after 6 weeks of treatment at the 30 mg dose level, but had progressive disease (PD) at week 11.
    DOI:
    10.1038/s41467-022-34782-9